Elon Musk: The Economy Will Be 10x the Size in 10 Years | #239

The protocol emerged from a conversation where Musk complained about failed neck surgeries and persistent back pain, calling for AI to solve back pain. Diamandis immediately offered his clinic’s resources, suggesting that full-body scans could uncover the mechanical issues and his proprietary list would point to reparative treatments. The exchange underscores a frustration with conventional medicine’s inability to fix chronic pain and proposes a new workflow: image, diagnose at the structural level, then apply emerging regenerative therapies. While the list itself was not detailed, the promise ties to Diamandis’s broader longevity network, including David Sinclair’s epigenetic reprogramming work.

Diamandis reveals that Sinclair's team is moving into human trials with a therapy that could repair joints, a major cause of back pain. He notes a recent paper showing joint repair, which may translate to human back pain elimination. Musk later expresses frustration with his own chronic back pain and neck surgeries, underscoring the massive unmet need. Diamandis emphasizes that solving back pain would dramatically raise global happiness, as it's a near-universal problem. The conversation links epigenetic reprogramming to a future where advanced diagnostics (Fountain Life) and therapies converge to extend healthspan. The therapy, ERW 100, is a partial reprogramming that doesn't erase cell identity but resets epigenomic marks, triggering repair. This is still in trials, but Diamandis seems confident it could address joint wear and tear.

Musk argues that AI and robotics will generate so much output that goods and services far exceed the money supply, causing massive deflation. He uses an energy scaling analogy: if Earth's electricity usage increased a millionfold, it would still be just a trillionth of the sun's output. In his view, we are at the beginning of a series of overlapping S-curves of AI progress, and the economy will explode as intelligence becomes abundant. The prediction builds on his earlier statements about universal high income and dematerialization of the monetary system.

Musk states that the final stages of Optimus 3 design are nearly complete and it will be the most advanced robot in the world, with nothing close. Production will follow an S-curve, starting slowly and ramping to high volume by mid-2026. He plans annual releases of improved models (Optimus 4 next year). He also mentions a 9.5 million square foot factory for Optimus, separate from the existing Tesla Gigafactory. The long-term aim is to vastly increase per-person output at Tesla while not cutting headcount, with robots eventually performing many factory tasks.

Musk explains that every successive model is built with help from the previous one, with humans gradually stepping out of the loop. He sees this as a hard takeoff already underway, with breakthroughs occurring so fast they are hard to track. The full automation of model improvement might arrive by end of 2025 or early next year. He ties this to Grok's current state: Grok 4.20 excels at prediction, but coding lags behind competitors and will catch up by mid-year.

Musk argues that when output of goods and services far exceeds the money supply, deflation ensues, and eventually AI will care only about power and mass, not human currency. He envisions a future where universal high income is simply 'issuing money' because production capacity outruns demand, and eventually even money ceases to be relevant. He compares it to Iain Banks' Culture novels. His own wealth is described as a percentage of companies creating useful things, not a liquid fortune.

Diamandis repeatedly invites Musk to his Dallas clinic, offering a list of therapeutics after scans. Musk questions the value of scans without interpretation, and Diamandis counters that he has a curated follow-up plan. The exchange highlights the gap between having data and taking action, and positions Fountain Life as the bridge. The service aligns with the theme of using technology to radically improve health outcomes, from pinpointing joint issues to potentially deploying emerging therapies like epigenetic reprogramming.